Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 1127

1.

Repeated measures latent class analysis of daily smoking in three smoking cessation studies.

McCarthy DE, Ebssa L, Witkiewitz K, Shiffman S.

Drug Alcohol Depend. 2016 Jun 6. pii: S0376-8716(16)30142-9. doi: 10.1016/j.drugalcdep.2016.05.025. [Epub ahead of print]

PMID:
27317043
2.

An update on the pharmacotherapeutic interventions for smoking cessation.

Barboza JL, Patel R, Patel P, Hudmon KS.

Expert Opin Pharmacother. 2016 Jun 20:1-14. [Epub ahead of print]

PMID:
27267498
3.

Bupropion and Naltrexone for Smoking Cessation: A Double-Blind Randomized Placebo-Controlled Clinical Trial.

Mooney ME, Schmitz JM, Allen S, Grabowski J, Pentel P, Oliver A, Hatsukami DK.

Clin Pharmacol Ther. 2016 May 23. doi: 10.1002/cpt.402. [Epub ahead of print]

PMID:
27213949
4.

Effects of aging on the effectiveness of smoking cessation medication.

Scholz J, Lima Santos PC, Buzo CG, Moreira Lopes NH, Abe TM, Gaya PV, Pierri H, Amorim C, Pereira AC.

Oncotarget. 2016 Apr 28. doi: 10.18632/oncotarget.9090. [Epub ahead of print]

5.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T.

Cochrane Database Syst Rev. 2016 May 9;(5):CD006103. doi: 10.1002/14651858.CD006103.pub7. Review.

PMID:
27158893
6.

Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.

Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, Ascher J, Russ C, Krishen A, Evins AE.

Lancet. 2016 Apr 22. pii: S0140-6736(16)30272-0. doi: 10.1016/S0140-6736(16)30272-0. [Epub ahead of print]

PMID:
27116918
7.

Are Smoking Cessation Treatments Associated with Suicidality Risk? An Overview.

Penberthy JK, Penberthy JM, Harris MR, Nanda S, Ahn J, Martinez CP, Osika AO, Slepian ZA, Forsyth JC, Starr JA, Farrell JE, Hook JN.

Subst Abuse. 2016 Apr 12;10:19-30. doi: 10.4137/SART.S33389. eCollection 2016. Review.

8.

How can we Improve on Modeling Nicotine Addiction to Develop Better Smoking Cessation Treatments?

Shoaib M, Buhidma Y.

Int Rev Neurobiol. 2016;126:121-56. doi: 10.1016/bs.irn.2016.02.008. Epub 2016 Mar 14.

PMID:
27055613
9.

Rapid assessment of the demand and supply of tobacco dependence pharmacotherapy in Uganda.

Kirenga BJ, Jones R, Muhofa A, Nyakoojo G, Williams S.

Public Health Action. 2016 Mar 21;6(1):35-7. doi: 10.5588/pha.15.0070. Epub 2016 Feb 17.

10.

Trends in Use of Medications for Smoking Cessation in Medicare, 2007-2012.

Jarlenski M, Hyon Baik S, Zhang Y.

Am J Prev Med. 2016 Mar 29. pii: S0749-3797(16)00098-2. doi: 10.1016/j.amepre.2016.02.018. [Epub ahead of print]

PMID:
27036506
11.

Analysis of Driving Factors of Willingness to Use and Willingness to Pay for Existing Pharmacological Smoking Cessation Aids Among Young and Middle-Aged Adults in Germany.

Aumann I, Treskova M, Hagemann N, von der Schulenburg JM.

Appl Health Econ Health Policy. 2016 Mar 28. [Epub ahead of print]

PMID:
27021824
12.

Combined pharmacotherapy and behavioural interventions for smoking cessation.

Stead LF, Koilpillai P, Fanshawe TR, Lancaster T.

Cochrane Database Syst Rev. 2016 Mar 24;3:CD008286. doi: 10.1002/14651858.CD008286.pub3. Review.

PMID:
27009521
13.

Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessation.

Annemans L, Marbaix S, Nackaerts K, Bartsch P.

Prev Med Rep. 2015 Mar 14;2:189-95. doi: 10.1016/j.pmedr.2015.03.004. eCollection 2015.

14.

Combination bupropion SR and varenicline for smoking cessation: a systematic review.

Vogeler T, McClain C, Evoy KE.

Am J Drug Alcohol Abuse. 2016 Mar;42(2):129-39. doi: 10.3109/00952990.2015.1117480. Epub 2016 Jan 25.

PMID:
26809272
15.

Cardiac adverse effects of nicotine replacement therapy.

[No authors listed]

Prescrire Int. 2015 Dec;24(166):292-3. Review.

PMID:
26788573
16.

Influence of smoking cessation drugs on blood pressure and heart rate in patients with cardiovascular disease or high risk score: real life setting.

Silva AP, Scholz J, Abe TO, Pinheiro GG, Gaya PV, Pereira AC, Santos PC.

BMC Cardiovasc Disord. 2016 Jan 5;16:2. doi: 10.1186/s12872-015-0180-4.

17.

The safety of treatments for tobacco use disorder.

Little MA, Ebbert JO.

Expert Opin Drug Saf. 2016 Mar;15(3):333-41. doi: 10.1517/14740338.2016.1131817. Epub 2015 Dec 30.

PMID:
26715118
18.

The Quit Experience and Concerns of Smokers With Psychiatric Illness.

Tulloch HE, Pipe AL, Clyde MJ, Reid RD, Els C.

Am J Prev Med. 2016 Jun;50(6):709-18. doi: 10.1016/j.amepre.2015.11.006. Epub 2015 Dec 17.

PMID:
26711162
19.

Pharmacological interventions for promoting smoking cessation during pregnancy.

Coleman T, Chamberlain C, Davey MA, Cooper SE, Leonardi-Bee J.

Cochrane Database Syst Rev. 2015 Dec 22;(12):CD010078. doi: 10.1002/14651858.CD010078.pub2. Review.

PMID:
26690977
20.

Update on medicines for smoking cessation.

McDonough M.

Aust Prescr. 2015 Aug;38(4):106-11. Epub 2015 Aug 3. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk